Summary
- The Federal Circuit has denied Insulet Corp.'s request to maintain an injunction against EOFlow Co. Ltd. during its appeal of a $59 million trade secrets jury verdict.
- This decision comes as Insulet seeks to challenge the jury's ruling at the U.S. Supreme Court.
- The outcome could significantly impact the competitive landscape in the insulin product market.
- Legal experts are closely monitoring the case for its implications on trade secret protections and corporate litigation strategies.
Join the discussion ā sign up to comment, upvote, and save articles.